logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Careers
  • SERVICES
    • Our Services
      • Comprehensive Market Access Launch Strategy
      • Market Access Landscape Analysis
      • HTA Planning and Reimbursement Evidence Strategy
      • Negotiation & Stakeholder Engagement Strategy
      • Portfolio & Life Cycle Strategy
      • Expert-Led Training & Customized Workshops
  • REPORTS
    • NEW – Order CRaFT 2025
    • DRD Market Access Trends & Insights
    • Oncology Market Access Trends & Insights
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
    • From Model to Market (MORSE x CCX Workshop)
  • LINKS
  • CONTACT US
logo-top-r
logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Careers
  • SERVICES
    • Our Services
      • Comprehensive Market Access Launch Strategy
      • Market Access Landscape Analysis
      • HTA Planning and Reimbursement Evidence Strategy
      • Negotiation & Stakeholder Engagement Strategy
      • Portfolio & Life Cycle Strategy
      • Expert-Led Training & Customized Workshops
  • REPORTS
    • NEW – Order CRaFT 2025
    • DRD Market Access Trends & Insights
    • Oncology Market Access Trends & Insights
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
    • From Model to Market (MORSE x CCX Workshop)
  • LINKS
  • CONTACT US

RWE and OBA Working Group 2019 Findings & Executive Summary

November 26, 2019
-
Market Access News, Publications
-
Posted by MORSE - < 1 min read.

The 2019 Real-World Evidence and Outcomes-Based Agreements Working Group research and outputs executive summary report is now available.

 

Download The Report

 

The mission of the Real-World Evidence and Outcomes-Based Agreements Working Group is to advance the opportunity for the use of outcomes-based agreements in Canada.

The working group’s 2019 primary focus was on research and analysis to bring clarity on the opportunity for OBAs in Canada, and to develop a framework for OBA implementation in Canada. Please direct any inquiries about this report to info@20sense.ca.

 

To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.

Share
Tags
CADTH
IHE
OBA
PBRSA
pCODR
pCPA
Reimbursement
Reimbursement strategy
RWD
RWE
← PREVIOUS POST
Summary of the CADTH Drug Portfolio Information Session November 2019
NEXT POST →
The workload at pCPA appears to have stabilized over 2019

Contact Us

MORSE Consulting Inc.

Toronto | Ottawa, Canada

+1-647-717-3179 (Toronto)

+1-613-864-8645 (Ottawa)

info@morseconsulting.ca

NEW A one-day interactive training and scenario-based modelling experience!
A one-day interactive training and scenario-based modelling experience!
Order 2025 Report

2025 Canadian Reimbursement and Forecasting Timelines Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
Social
Connect & Follow:
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
RWE and OBA Working Group 2019 Findings & Executive Summary
Learn More
Learn More